DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0069221A1 Kosoglou Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0069221A1 Kosoglou Et Al US 2003OO69221A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0069221A1 KOSOglou et al. (43) Pub. Date: Apr. 10, 2003 (54) COMBINATIONS OF STEROL ABSORPTION Related U.S. Application Data INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF (60) Provisional application No. 60/323,842, filed on Sep. WASCULAR CONDITIONS 21, 2001. Provisional application No. 60/264,396, filed on Jan. 26, 2001. Provisional application No. (75) Inventors: Teddy Kosoglou, Jamison, PA (US); 60/264,600, filed on Jan. 26, 2001. Provisional appli Rudyard J. Ress, Flemington, NJ (US); cation No. 60/264,275, filed on Jan. 26, 2001. John T. Strony, Lebanon, NJ (US); Enrico P. Veltri, Princeton, NJ (US); Publication Classification William Hauer, Warren, NJ (US) (51) Int. Cl. ................................................ A61K 31/397 Correspondence Address: (52) U.S. Cl. ........................................................ 514/210.02 SCHERING-PLOUGH CORPORATION PATENT DEPARTMENT (K-6-1, 1990) (57) ABSTRACT 2000 GALLOPING HILL ROAD KENILWORTH, NJ 07033-0530 (US) The present invention provides compositions, therapeutic (73) Assignee: Schering Corporation combinations and methods including: (a) at least one Sterol absorption inhibitor and (b) at least one cardiovascular agent (21) Appl. No.: 10/057,339 different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and (22) Filed: Jan. 25, 2002 lowering plasma levels of Sterols. US 2003/0069221A1 Apr. 10, 2003 COMBINATIONS OF STEROL ABSORPTION ever means, less cholesterol is delivered to the liver. The INHIBITOR(S) WITH CARDIOVASCULAR consequence of this action is decreased hepatic lipoprotein AGENT(S) FOR THE TREATMENT OF WASCULAR (VLDL) production and an increase in the hepatic clearance CONDITIONS of plasma cholesterol, mostly as LDL. Thus, the net effect of inhibiting intestinal cholesterol absorption is a decrease in CROSS-REFERENCE TO RELATED plasma cholesterol levels. APPLICATIONS 0007 U.S. Pat. Nos. 5,767,115, 5,624,920, 5,668,990, 0001. This application claims the benefit of priority from 5,656,624 and 5,688,787, respectively, disclose hydroxy U.S. Provisional Patent Application Serial No. 60/323,842 Substituted azetidinone compounds and Substituted B-lactam filed Sep. 21, 2001, U.S. Provisional Patent Application compounds useful for lowering cholesterol and/or in inhib Serial No. 60/264,396 filed Jan. 26, 2001, U.S. Provisional iting the formation of cholesterol-containing lesions in Patent Application Serial No. 60/264,600 filed Jan. 26, 2001, mammalian arterial walls. U.S. Pat. Nos. 5,846,966 and and U.S. Provisional Patent Application Serial No. 60/264, 5,661,145, respectively, disclose hydroxy-Substituted azeti 275 filed Jan. 26, 2001, each incorporated herein by refer dinone compounds or Substituted B-lactam compounds in CCC. combination with HMG CoA reductase inhibitors for pre venting or treating atherosclerosis and reducing plasma FIELD OF THE INVENTION cholesterol levels. 0002 The present invention relates to methods, compo 0008 PCT Patent Application No. WO 00/38725 dis Sitions and therapeutic combinations comprising certain closes cardiovascular therapeutic combinations including an cardiovascular agents and Sterol absorption inhibitors for ileal bile acid transport inhibitor or cholesteryl ester trans treating atherOSclerosis, coronary artery disease and other port protein inhibitor in combination with a fibric acid derivative, nicotinic acid derivative, microSomal triglyceride vascular conditions in mammals. transfer protein inhibitor, cholesterol absorption antagonist, phytosterol, Stanol, antihypertensive agent or bile acid BACKGROUND OF THE INVENTION Sequestrant. 0.003 Vascular disease is a term that broadly encom 0009 U.S. Pat. No. 5,698,527 discloses ergostanone passes all disorders of blood vessels including Small and derivatives Substituted with disaccharides as cholesterol large arteries and veins and blood flow. The most prevalent absorption inhibitors, employed alone or in combination form of vascular disease is arterioSclerosis, a condition with certain other cholesterol lowering agents, which are associated with the thickening and hardening of the arterial useful in the treatment of hypercholesterolemia and related wall. Arteriosclerosis of the large vessels is referred to as disorders. atherosclerosis. Atherosclerosis is the predominant underly ing factor in vascular disorderS Such as coronary artery 0010. Other vascular conditions frequently coexist with disease, aortic aneurysm, arterial disease of the lower cholesterol levels associated with atherosclerosis. These extremities and cerebrovascular disease. may include hypertension, angina and/or arrhythmia. The relevance of, for example, elevated blood pressure as a risk 0004 One major risk factor for arteriosclerosis is high factor for atherosclerosis, cardiovascular and cerebrovascu Serum cholesterol. A total cholesterol level in excess of lar disease in both men and women has been clarified in a 225-250 mg/dl is associated with significant elevation of risk large number of epidemiological Studies. of vascular disease, particularly coronary heart disease. 0011 Clinical trials of blood pressure lowering using 0005 Cholesteryl esters are a major component of ath cardiovascular agents including, for example, calcium chan erosclerotic lesions and the major Storage form of choles nel blockers, have shown beneficial effects in the treatment terol in arterial wall cells. Formation of cholesteryl esters is of early atheroscleroticlesions (see, e.g., Lichtien, P. R. et al. also a step in the intestinal absorption of dietary cholesterol. :Lancet, 335: 1109-1113 (1990) and Waters, D. et al. Cir Thus, inhibition of cholesteryl ester formation and reduction culation 82: 1940-1953 (1990)). Scott (PCT patent Appli of Serum cholesterol can inhibit the progression of athero cation No. WO 99/11260) describes combinations of an Sclerotic lesion formation, decrease the accumulation of HMG CoA reductase inhibitor with an antihypertensive cholesteryl esters in the arterial wall, and block the intestinal agent for the treatment of atherosclerosis and other Symp absorption of dietary cholesterol. toms of vascular disease risk. Additionally, Egon et al. (PCT 0006 The regulation of whole-body cholesterol homeo Patent Application No. WO 96/40255) describe a combina Stasis in mammals and animals involves the regulation of tion therapy of antihypertensive agents including eplerenone dietary cholesterol and modulation of cholesterol biosynthe and angiotensin II antagonist for treating cardiovascular sis, bile acid biosynthesis and the catabolism of the choles disease. terol-containing plasma lipoproteins. The liver is the major 0012 Despite recent improvements in the treatment of organ responsible for cholesterol biosynthesis and catabo vascular disease, there remains a need in the art for lism and, for this reason, it is a prime determinant of plasma improved compositions and treatments for atherosclerosis, cholesterol levels. The liver is the site of synthesis and other vascular diseases and conditions associated with vas secretion of very low density lipoproteins (VLDL) which are cular diseases Such as hypertension, atherosclerosis, and Subsequently metabolized to low density lipoproteins (LDL) hyperlipidaemia. in the circulation. LDL are the predominant cholesterol carrying lipoproteins in the plasma and an increase in their SUMMARY OF THE INVENTION concentration is correlated with increased atherosclerosis. 0013 In one embodiment the present invention provides When intestinal cholesterol absorption is reduced, by what a composition comprising (a) at least one Sterol absorption US 2003/0069221A1 Apr. 10, 2003 inhibitor or pharmaceutically acceptable Salt or Solvate 0020 “Cardiovascular agents” which may used to treat thereof or prodrug of the at least one Sterol absorption the vascular conditions of the present invention, obesity or inhibitor or of the salt or solvate thereof; and (b) at least one diabetes and/or to reduce the level of Sterol(s) in the plasma, cardiovascular agent for treating a vascular condition, dia as used herein, are members of different classes, including betes, obesity and/or lowering a concentration of a Sterol in calcium channel blockers, angiotensin-converting enzyme plasma of a mammal which is different from the at least one (ACE) inhibitors, angiotensin-II receptor antagonists, sterol absorption inhibitor. diuretics, adrenergic blockers including beta-adrenergic 0.014. Therapeutic combinations also are provided com receptor blockers and alpha-adrenergic receptor blockers, prising: (a) a first amount of at least one sterol absorption adrenergic Stimulants, coronary vasodilators, antihyperten inhibitor or pharmaceutically acceptable Salt or Solvate Sive agents, diuretics, anti-anginal agents and combinations thereof or prodrug of the at least one Sterol absorption thereof. The phrase “cardiovascular agents' as used herein inhibitor or of the salt or solvate thereof; and (b) a second does not include HMGCoA reductase inhibitors. The car amount of at least one cardiovascular agent for treating a diovascular agents as defined above are chemically or Struc vascular condition in a mammal which is different from the turally different from the sterol absorption inhibitor(s) dis at least one sterol absorption inhibitor, wherein the first cussed below, for example, they contain one or more amount and the Second amount
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • WO 2017/031289 Al 23 February 2017 (23.02.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/031289 Al 23 February 2017 (23.02.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A01N 25/04 (2006.01) A01N 25/24 (2006.01) kind of national protection available): AE, AG, AL, AM, A 59/00 (2006.01) AOIN25/26 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A0 33/12 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 16/047509 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 18 August 2016 (18.08.2016) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/207,750 20 August 2015 (20.08.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: INTEGRICOTE, INC.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Inhibition of G Protein-Activated Inwardly Rectifying K Channels by Phencyclidine
    244 Current Neuropharmacology, 2011, 9, 244-246 Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by Phencyclidine Toru Kobayashi1,2,*, Daisuke Nishizawa1 and Kazutaka Ikeda1 1Division of Psychobiology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan; 2Department of Project Programs, Center for Bioresource-based Researches, Brain Research Institute, Niigata University, 1-757 Asahimachi, Chuo-ku, Niigata, Niigata 951-8585, Japan Abstract: Addictive drugs, such as opioids, ethanol, cocaine, amphetamine, and phencyclidine (PCP), affect many functions of the nervous system and peripheral organs, resulting in severe health problems. G protein-activated inwardly rectifying K+ (GIRK, Kir3) channels play an important role in regulating neuronal excitability through activation of various Gi/o protein-coupled receptors including opioid and CB1 cannabinoid receptors. Furthermore, the channels are directly activated by ethanol and inhibited by cocaine at toxic levels, but not affected by methylphenidate, methampheta- mine, and 3,4-methylenedioxymethamphetamine (MDMA) at toxic levels. The primary pharmacological action of PCP is blockade of N-methyl-D-aspartate (NMDA) receptor channels that are associated with its psychotomimetic effects. PCP also interacts with several receptors and channels at relatively high concentrations. However, the molecular mechanisms underlying the various effects of PCP remain to be clarified. Here, we investigated the effects of PCP on GIRK channels using the Xenopus oocyte expression system. PCP weakly but significantly inhibited GIRK channels at micromolar concentrations, but not Kir1.1 and Kir2.1 channels. The PCP concentrations effective in inhibiting GIRK channels overlap clinically relevant brain concentrations in severe intoxication. The results suggest that partial inhibition of GIRK channels by PCP may contribute to some of the toxic effects after overdose.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Effect of the Titanium Isopropoxide:Acetylacetone Molar Ratio on the Photocatalytic Activity of Tio2 Thin Films
    molecules Article Effect of the Titanium Isopropoxide:Acetylacetone Molar Ratio on the Photocatalytic Activity of TiO2 Thin Films Jekaterina Spiridonova 1,* , Atanas Katerski 1, Mati Danilson 2 , Marina Krichevskaya 3,* , Malle Krunks 1 and Ilona Oja Acik 1,* 1 Laboratory of Thin Films Chemical Technologies, Department of Materials and Environmental Technology, Tallinn University of Technology, Ehitajate tee 5, 19086 Tallinn, Estonia; [email protected] (A.K.); [email protected] (M.K.) 2 Laboratory of Optoelectronic Materials Physics, Department of Materials and Environmental Technology, Tallinn University of Technology, Ehitajate tee 5, 19086 Tallinn, Estonia; [email protected] 3 Laboratory of Environmental Technology, Department of Materials and Environmental Technology, Tallinn University of Technology, Ehitajate tee 5, 19086 Tallinn, Estonia * Correspondence: [email protected] (J.S.); [email protected] (M.K.); [email protected] (I.O.A.); Tel.: +372-620-3369 (I.O.A.) Academic Editors: Smagul Karazhanov, Ana Cremades and Cuong Ton-That Received: 31 October 2019; Accepted: 25 November 2019; Published: 27 November 2019 Abstract: TiO2 thin films with different titanium isopropoxide (TTIP):acetylacetone (AcacH) molar ratios in solution were prepared by the chemical spray pyrolysis method. The TTIP:AcacH molar ratio in spray solution varied from 1:3 to 1:20. TiO2 films were deposited onto the glass substrates at 350 ◦C and heat-treated at 500 ◦C. The morphology, structure, surface chemical composition, and photocatalytic activity of the obtained TiO2 films were investigated. TiO2 films showed a transparency of ca 80% in the visible spectral region and a band gap of ca 3.4 eV irrespective of the TTIP:AcacH molar ratio in the spray solution.
    [Show full text]
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T
    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
    [Show full text]
  • Certain Pharmaceuticals and Intermediate Chemicals: Identification of Applicable 6-Digit HS Subheadings for Products Covered By
    Second Interim Report to the Public on CERTAIN PHARMACEUTICALS AND INTERMEDIATE CHEMICALS: IDENTIFI­ CATION OF APPLICABLE 6-DIGIT HS SUBHEADINGS. .· FOR PRODUCTS ·coVERED BY THE PROPOSED URUGUAY ROUND PHARMACEUTICAL A,GREEMENT Investigation No. 332-322 USITC PUBLICATION 2500 APRIL 1992 ,f~· United States International Trade Commission . ·J, Washington, DC 20436 . ·-~}~~:; . _:, -~;<$f ·!•;. UNITED STATES INTERNATIONAL TRADE COMMISSION COMMISSIONERS Don E. Newquist, Chairman Anne E. Brunsdale, Vice Chairman David B. Rohr Carol T. Crawford Janet A. Nuzum Peter S. Watson Office of Operations Charles W. Ervin, Director Office of Industries Rohen A. Rogowsky, Director This report was prepared principally by Eli?.abcth R. Ncsbiu Project Leader Aimison Jonnard Edward Matusik David Michels James Raftery Office of Industries David Beck Office of Tariff Affairs and Trade Agreements With assistance from Paul Daniels James Gill Office ofInformation Resources Management Under the direction of John J. Gersic, Chief Energy & Chemicals Division and Edmund D. Cappuccilli, Chief Energy, Petroleum, Benzenoid Chemicals, and Rubber and Plastics Branch · Energy & Chemicals Division Additional assistance provided by Brenda Carroll and Keilh Hipp With special assistance from U.S. Customs Service Address all communications to Kenneth R. Mason, Secreta·ry to the Commission United States International Trade Commission Washington, DC 20436 PREFACE This report is the second of two interim reports to the public pertaining to Commission investigation No. 332-322, entitled Certain Pharmaceuticals and Intermediate Chemicals; Identification of Applicable 6-Digit HS Subheadings for Products Covered by the Proposed Uruguay Round Pharmaceutical Agreement. The investigation was instituted following receipt of a letter from the United States Trade Representative (USTR) on January 27, 1992, requesting that the Commission conduct an investigation under section 332(g) of the Tariff Act of 1930 (see appendix A for a copy of the USTR' s request)·.
    [Show full text]
  • Effect of Titanium Source and Sol-Gel Tio2 Thin Film Formation Parameters
    Materials Science-Poland, 38(3), 2020, pp. 424-433 http://www.materialsscience.pwr.wroc.pl/ DOI: 10.2478/msp-2020-0056 Effect of titanium source and sol-gel TiO2 thin film formation parameters on its morphology and photocatalytic activity PIOTR DULIAN∗,JAN ZAJIC,WITOLD Z˙ UKOWSKI Faculty of Chemical Engineering and Technology, Cracow University of Technology, 24 Warszawska St., 310155 Cracow, Poland TiO2 thin films with different surface structure have been prepared from alkoxide solutions by the sol-gel method using different cationic precursors and heat treatment techniques. The effect of using titanium isopropoxide as well as titanium butox- ide as a titanium source on the surface structure and photocatalytic activity of the resultant thin films was studied. Significant differences in the rate of hydrolysis and condensation reactions during the sol-gel synthesis were observed for these titanium precursors. This had a direct influence on the morphology of the as-prepared TiO2 films. Higher quality oxide coatings were obtained from titanium isopropoxide. They were characterized by a smaller grain size, improved surface roughness and uni- form coverage of the glass substrate. A beneficial effect of calcination process after each sol application cycle in contrast to single step calcination after all dip-coating cycles was observed. Photocatalytic degradation tests showed that methyl orange was decolorized in the presence of all prepared TiO2 films by exposing their aqueous solutions to UV light (λ = 254 nm). The highest photocatalytic activity had the TiO2 layer produced using titanium isopropoxide. Keywords: TiO2 thin film; sol-gel; photocatalysis 1. Introduction and corrosion protection [5–12]. Currently, several techniques for producing thin semiconductor lay- Environmental pollution is one of the main ers [13–17] are known.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0155676 A1 Burnett Et Al
    US 20070 155676A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0155676 A1 Burnett et al. (43) Pub. Date: Jul. 5, 2007 (54) SUBSTITUTED AZETIONONE (60) Provisional application No. 60/452,725, filed on Mar. COMPOUNDS, PROCESSES FOR 7, 2003. PREPARING THE SAME, FORMULATIONS AND USES THEREOF Publication Classification (75) Inventors: Duane A. Burnett, Bernardsville, NJ (51) Int. Cl. (US); John W. Clader, Cranford, NJ A61K 3 1/7052 (2006.01) (US) A6II 3 L/506 (2006.01) A61K 31/4709 (2006.01) Correspondence Address: A61K 31/4025 (2006.01) SCHERING-PLOUGH CORPORATION A61K 31/4439 (2006.01) PATENT DEPARTMENT (K-6-1, 1990) A 6LX 3L/397 (2006.01) 2000 GALLOPNG HILL ROAD C07D 405/14 (2006.01) KENILWORTH, NJ 07033-0530 (US) C07D 405/02 (2006.01) (52) U.S. Cl. ..................... 514/23: 514/210.02:536/17.3; (73) Assignee: Schering Corporation, Kenilworth, NJ 54O72OO (21) Appl. No.: 11/708,449 (57) ABSTRACT Filed: Feb. 20, 2007 The present invention provides substituted azetidinone com (22) pounds, formulations and processes for preparing the same Related U.S. Application Data which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, (62) Division of application No. 10/792.346, filed on Mar. stroke, demyelination and lowering plasma levels of sterols 3, 2004, now Pat. No. 7,208,486. and/or stanols in a subject. US 2007/O 155676 A1 Jul. 5, 2007 SUBSTITUTED AZETIDINONE COMPOUNDS, 0006 U.S. Pat. Nos. 5,846,966 and 5,661,145, respec PROCESSES FOR PREPARING THE SAME, tively, disclose treatments for inhibiting atherosclerosis and FORMULATIONS AND USES THEREOF reducing plasma cholesterol levels using Such hydroxy Substituted aZetidinone compounds or Substituted B-lactam CROSS-REFERENCE TO RELATED compounds in combination with HMG CoA reductase APPLICATION inhibitor compounds, which act by blocking hydroxymeth 0001.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]